WALTHAM, Mass. — Thermo Fisher Scientific Inc. said it has enrolled the first patient in its new PPD CorEvitas Obesity Registry, a prospective, observational initiative designed to generate real-world evidence on the long-term effectiveness, safety, and patient experience associated with obesity management therapies, including anti-obesity medications.
The registry will collect insights directly from clinicians and patients to better understand treatment patterns, adherence, satisfaction, and clinical outcomes, including anthropomorphic measures, across a wide range of care settings. The company said the data are intended to reflect everyday clinical practice and support more informed decision-making in obesity care.
Obesity is a chronic and complex disease influenced by genetic, environmental, and psychosocial factors and is associated with significant comorbidities such as type 2 diabetes, heart disease, and certain cancers. It also affects quality of life, mobility, and mental health. In the United States, more than 100 million adults live with obesity, including more than 22 million with severe obesity. Globally, the economic impact of overweight and obesity is projected to reach $3 trillion annually by 2030 and rise to more than $18 trillion by 2060.
“The CorEvitas Obesity Registry represents a major step forward in understanding the use and outcomes associated with obesity treatments in everyday clinical practice,” said Leslie Harrold, M.D., vice president and global head of real-world science and strategy for PPD CorEvitas Clinical Registries at Thermo Fisher Scientific. “Insights generated from this robust, real-world evidence base will inform the healthcare community on treatment effectiveness, safety and the patient experience associated with obesity care, which will advance care for millions living with the condition.”
According to the company, the registry is designed to capture detailed physician- and patient-reported outcomes to provide a clearer picture of disease progression, treatment response, and the challenges patients face throughout their care journey. Findings from the initiative are expected to inform clinical practice, guide future research, and support the development of evidence-based strategies for obesity management.
The obesity registry is the 15th independent registry established under the PPD CorEvitas Clinical Registries program, part of Thermo Fisher Scientific’s PPD clinical research business. The CorEvitas Clinical Registries platform includes proprietary disease registries with structured, regulatory-grade clinical data from more than 500 investigator sites and longitudinal data on over 100,000 patients. The company said its independent registry model has been accepted by regulators for long-term post-authorization safety studies across multiple disease areas.
